当前位置: 首页 > 期刊 > 《中国医药导报》 > 2018年第15期
编号:1358344
IgA肾病残余蛋白尿非免疫抑制剂药物治疗进展
http://www.100md.com 2018年8月31日 中国医药导报 2018年第15期
     胡妍琦 李六生

    [摘要] IgA腎病在全球范围内是导致终末期肾病的主要原因,任何能减少蛋白尿干预措施均有利于延缓IgA肾病进展。目前肾素-血管紧张素系统抑制剂的应用有时并不能使IgA肾病蛋白尿完全缓解,往往需要其他非免疫抑制剂药物治疗,包括鱼油、活性维生素D、舒洛地特、肾素抑制剂、醛固酮受体拮抗剂、他汀类药物等。该文结合国内外文献就IgA肾病残余蛋白尿非免疫抑制剂药物治疗进展作一综述。

    [关键词] IgA肾病;残余蛋白尿;非免疫抑制剂;药物治疗

    [中图分类号] R692.6 [文献标识码] A [文章编号] 1673-7210(2018)05(c)-0034-04

    Progress of non-immunosuppressant therapy for IgA nephropathy with residual proteinuria

    HU Yanqi LI Liusheng

    Department of Nephrology, People′s Hospital of China Three Gorges University, Hubei Province, Yichang 443000, China

    [Abstract] IgA nephropathy (IgAN) is a common cause of end stage renal disease in the world. Any intervention to reduce proteinuria is helpful to slow the progress of IgAN. At present,sometimes complete remission of IgAN with proteinuria cannot be achieved through the use of renin angiotensin system inhibitor, thus other non-immunosuppressant drugs, including fish oil, active vitamin D, Sulodexide, adrenergic inhibitor, aldosterone receptor blockade, statins and so on are often needed. By analyzing the related literature, this paper reviews the progress of non-immunosuppressant therapy for IgAN with residual proteinuria. ......

您现在查看是摘要页,全文长 15675 字符